Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Zaragoza – page 31

546 clinical trials in Zaragoza, Spain across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Zaragoza at a glance
546
clinical trials
  • Research sites3
Type of trial
Recruitment status
Quick filters

546 trials in Zaragoza

Open in trial search

Colorectal cancer metastatic

Not recruiting

Study of Nous-209 Genetic Vaccine and Pembrolizumab for Patients with Advanced Microsatellite Instability-High Colorectal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gad20-209-Fsp-A1
  • Sponsor:Nouscom S.r.l.

Neovascular age-related macular degeneration

Not recruiting

Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Opthea Limited

Gastric cancer+2

Not recruiting

Study of Domvanalimab, Zimberelimab, and Chemotherapy for Patients with Advanced Esophageal or Gastric Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Arcus Biosciences Inc.

Anaemia+1

Not recruiting

Study on KER-050 and Ruxolitinib for Patients with Myelofibrosis and Anemia

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Elritercept
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Not recruiting

Study on the Effects of Etrasimod Arginine for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Etrasimod Arginine
  • Sponsor:Arena Pharmaceuticals Inc.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:Solti Group

HIV infection

Not recruiting

Study Comparing DTG/3TC and BIC/FTC/TAF for Maintaining HIV Control in Adults

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Fundacion Seimc Gesida

Liposarcoma

Not recruiting

Study Comparing BI 907828 and Doxorubicin for Patients with Advanced Dedifferentiated Liposarcoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:(3S,3'S,3A's,10A's)-6-Chloro-3'-(3-Chloro-2-Fluorophenyl)-1'-(Cyclopropylmethyl)-6'-Methyl-2-Oxo-1,2,3',3A',10',10A'-Hexahydro-1'H-Spiro[Indole-3,2'-Pyrrolo[2',3':4,5]Pyrrolo[1,2-B]Indazole]-7'-Carboxylic Acid
  • Sponsor:Boehringer Ingelheim Espana S.A.

Non-small cell lung cancer+2

Not recruiting

Study on the Safety of Continued Treatment with GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:H e x a l AG

Neoplasm

Not recruiting

Study of OMX-0407 for Patients with Previously Treated Unresectable Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Omx-0407
  • Sponsor:iOmx Therapeutics AG

Focal segmental glomerulosclerosis

Not recruiting

Study on the Effects of Sparsentan and Irbesartan for Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Irbesartan
  • Sponsor:Travere Therapeutics Inc.

Study of Buparlisib and Paclitaxel for Patients with Recurrent or Metastatic Head and Neck Cancer

Not recruiting
Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Buparlisib
  • Sponsor:Adlai Nortye USA Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Zaragoza

What the registry says about research in the country

01 Oncology & Hematology

Innovative research focusing on advanced cancer treatments and blood disorders, including studies of new therapies for lung cancer, pancreatic adenocarcinoma, and various hematologic malignancies.

  • Non-small cell lung cancer treatments
  • Chronic lymphocytic leukemia therapies
  • Soft tissue sarcoma management

Multiple trials evaluating combination therapies and novel treatment approaches for both solid tumors and blood cancers.

02 Autoimmune & Inflammatory Conditions

Research into treatments for various inflammatory and autoimmune disorders, with emphasis on chronic conditions affecting quality of life.

  • Plaque psoriasis treatments
  • Crohn's disease management
  • Thyroid eye disease therapies

Studies focusing on innovative biological therapies and targeted treatments for inflammatory conditions.

03 Cardiovascular & Metabolic Disorders

Studies addressing critical cardiovascular health challenges and metabolic conditions, including innovative approaches to stroke treatment and lipid management.

  • Acute cerebral ischemic stroke
  • Hypertriglyceridemia treatments
  • Cardiovascular disease prevention

Focus on developing new therapeutic options for both acute and chronic cardiovascular conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.